Carcinoma, Hepatocellular
Conditions
Brief summary
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
Detailed description
To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liver cancer treated with TACE combined with immunotherapy and targeted therapy and establish a specific individualized prognostic score and risk stratification model.
Interventions
OTHERImmunotherapy, targeted therapy.
Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
Sponsors
Qianfoshan Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* ≥18 years old, both men and women * primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings * patients with liver function Child-Pugh A or B (≤8 points) * BCLC stage B and stage C * expected survival time ≥8 weeks * patients with generally good performance status (ECOG PS score 0 or 1)
Exclusion criteria
* The patient's key data is missing * liver metastatic cancer confirmed by histology or cytology * patients who interrupt treatment due to intolerance of adverse drug reactions * combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc. * combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation * study participants known to have mental illness * situations such as drug use or substance abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free-Survival | 12 months | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. |
Countries
China
Contacts
Primary ContactJing Liang, Dr
Outcome results
None listed